In the last trading session, 3.71 million Kyverna Therapeutics Inc (NASDAQ:KYTX) shares changed hands as the company’s beta touched 3.13. With the company’s per share price at $3.28 changed hands at -$0.19 or -5.48% during last session, the market valuation stood at $141.76M. KYTX’s last price was a discount, traded about -247.56% off its 52-week high of $11.40. The share price had its 52-week low at $1.78, which suggests the last value was 45.73% up since then. When we look at Kyverna Therapeutics Inc’s average trading volume, we note the 10-day average is 0.73 million shares, with the 3-month average coming to 347.81K.
Analysts gave the Kyverna Therapeutics Inc (KYTX) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended KYTX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Kyverna Therapeutics Inc’s EPS for the current quarter is expected to be -1.04.
Kyverna Therapeutics Inc (NASDAQ:KYTX) trade information
Instantly KYTX was in red as seen at the end of in last trading. With action 6.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -57.62%, with the 5-day performance at 6.84% in the green. However, in the 30-day time frame, Kyverna Therapeutics Inc (NASDAQ:KYTX) is 28.63% up. Looking at the short shares, we see there were 2.1 million shares sold at short interest cover period of 4.51 days.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Kyverna Therapeutics Inc earnings to decrease by -11.70%, but the outlook for the next 5-year period is at -2.34% per year.
KYTX Dividends
Kyverna Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-13.
Kyverna Therapeutics Inc (NASDAQ:KYTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.04% of Kyverna Therapeutics Inc shares while 68.49% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 77.86%. There are 68.49% institutions holding the Kyverna Therapeutics Inc stock share, with VIDA VENTURES ADVISORS, LLC the top institutional holder. As of 2024-06-30, the company held 10.4901% of the shares, roughly 4.52 million KYTX shares worth $33.93 million.
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC holds the second largest percentage of outstanding shares, with 7.8106% or 3.37 million shares worth $25.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 806.42 shares estimated at $2.65 million under it, the former controlled 1.87% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.35% of the shares, roughly 585.13 shares worth around $1.92 million.
